Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pulse Biosciences ( (PLSE) ) has provided an announcement.
On April 7, 2026 Pulse Biosciences announced it had enrolled and treated the first seven patients in its NANOPULSE-AF IDE pivotal clinical study evaluating the nPulse Cardiac Catheter System for recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation. The non-randomized trial, led initially at St. Bernards Medical Center in Arkansas and overseen by global principal investigator Dr. Vivek Reddy, aims to enroll about 215 patients across up to 30 centers in the U.S. and Europe, with primary safety and efficacy endpoints assessed at six and twelve months post-ablation.
The launch of this pivotal study follows a first-in-human feasibility trial in Europe that reported 96% procedural success at 12 months and 100% acute success without anti-arrhythmic drugs, outperforming typical recurrence rates of 20% to 25%. By combining ultra-fast, non-thermal nsPFA energy with integrated 3D electroanatomical mapping from Abbott’s EnSite X system, Pulse Biosciences is positioning its nPulse catheter as a differentiated AF ablation technology that promises precise, durable pulmonary vein isolation, shorter procedure times and a more streamlined workflow, potentially strengthening the company’s competitive standing in the growing AF ablation market.
The most recent analyst rating on (PLSE) stock is a Hold with a $23.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, large losses, and accelerating cash burn). Offsetting this are improving technicals and encouraging clinical/regulatory progress communicated on the earnings call and reinforced by recent product-focused updates, though valuation support remains limited given ongoing losses and no dividend.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences, Inc. is a bioelectric medicine company developing its proprietary nPulse nanosecond pulsed field ablation technology to non-thermally clear cells while sparing adjacent non-cellular tissue. The company is initially targeting treatment of atrial fibrillation and select soft tissue ablation markets where its nsPFA platform could materially impact patient care and procedural efficiency.
Average Trading Volume: 340,632
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.56B
See more insights into PLSE stock on TipRanks’ Stock Analysis page.